The request for an extension by Novo Nordisk to respond to regulatory inquiries about Ozempic's pricing could lead to uncertainty among investors regarding potential regulatory actions or negative publicity. However, without immediate negative consequences outlined in the news, the impact is considered neutral until more information becomes available.